Matches in SemOpenAlex for { <https://semopenalex.org/work/W2588961334> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2588961334 endingPage "107" @default.
- W2588961334 startingPage "107" @default.
- W2588961334 abstract "107 Background: Approximately 15-20% of all breast cancers account for triple-negative breast cancers that exhibit aggressive, distinct metastatic pattern and poor prognosis. More than 50% of patients with triple negative breast cancers develop chemoresistance and do not respond to chemotherapeutic drugs, leading to early relapse and shorter survival. Understanding the mechanisms underlying such resistance is therefore crucial for the development of new, efficacious cancer drugs. Methods: Through high-throughput miRNA inhibitor library screens, we have identified miRNA inhibitors that sensitize resistant triple negative breast cancer cells to paclitaxel, a drug commonly used to treat triple negative breast cancers. Results: Through high-throughput miRNA inhibitor library screens, we have identified miRNA inhibitors that sensitize resistant triple negative breast cancer cells to paclitaxel, a drug commonly used to treat triple negative breast cancers. Since miRNAs are endogenously expressed and can be easily manipulated using synthetic oligoribonucleotides, we believe that they represent more attractive targets than the single gene or gene product that is the target of conventional cancer treatments that are typically prone to drug resistance. Supporting this, we have recently demonstrated that miRNAs can be systemically delivered to treat breast cancer lung metastasis without any hepatotoxicity. In addition to being a potent therapeutic regimen, our preliminary analyses reveal that miRNAs can be bonafide early prognostic markers to monitor treatment response to specific drugs in triple-negative breast cancers. Conclusions: Taken together, these findings suggest that miRNA can serve as potent therapeutic adjuvants and although the data content of miRNA profiles is far less than that of gene expression profiles, by virtue of their ability to modulate entire spectrum of genes and pathways miRNAs have potential to be better classifiers for the prognosis and response to treatment of cancers. We believe that the identification of miRNAs that mediate chemoresistance could lead to more efficient treatment selection at the patient level and an improved response rates at the population level." @default.
- W2588961334 created "2017-02-24" @default.
- W2588961334 creator A5059637384 @default.
- W2588961334 creator A5080875837 @default.
- W2588961334 date "2012-09-20" @default.
- W2588961334 modified "2023-09-25" @default.
- W2588961334 title "Improving the efficacy of chemotherapy drugs for the treatment of triple-negative breast cancers." @default.
- W2588961334 doi "https://doi.org/10.1200/jco.2012.30.27_suppl.107" @default.
- W2588961334 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28146725" @default.
- W2588961334 hasPublicationYear "2012" @default.
- W2588961334 type Work @default.
- W2588961334 sameAs 2588961334 @default.
- W2588961334 citedByCount "0" @default.
- W2588961334 crossrefType "journal-article" @default.
- W2588961334 hasAuthorship W2588961334A5059637384 @default.
- W2588961334 hasAuthorship W2588961334A5080875837 @default.
- W2588961334 hasConcept C104317684 @default.
- W2588961334 hasConcept C114851261 @default.
- W2588961334 hasConcept C121608353 @default.
- W2588961334 hasConcept C126322002 @default.
- W2588961334 hasConcept C143998085 @default.
- W2588961334 hasConcept C145059251 @default.
- W2588961334 hasConcept C2776694085 @default.
- W2588961334 hasConcept C2777292972 @default.
- W2588961334 hasConcept C2779013556 @default.
- W2588961334 hasConcept C2780110267 @default.
- W2588961334 hasConcept C502942594 @default.
- W2588961334 hasConcept C530470458 @default.
- W2588961334 hasConcept C55493867 @default.
- W2588961334 hasConcept C71924100 @default.
- W2588961334 hasConcept C86803240 @default.
- W2588961334 hasConcept C89423630 @default.
- W2588961334 hasConceptScore W2588961334C104317684 @default.
- W2588961334 hasConceptScore W2588961334C114851261 @default.
- W2588961334 hasConceptScore W2588961334C121608353 @default.
- W2588961334 hasConceptScore W2588961334C126322002 @default.
- W2588961334 hasConceptScore W2588961334C143998085 @default.
- W2588961334 hasConceptScore W2588961334C145059251 @default.
- W2588961334 hasConceptScore W2588961334C2776694085 @default.
- W2588961334 hasConceptScore W2588961334C2777292972 @default.
- W2588961334 hasConceptScore W2588961334C2779013556 @default.
- W2588961334 hasConceptScore W2588961334C2780110267 @default.
- W2588961334 hasConceptScore W2588961334C502942594 @default.
- W2588961334 hasConceptScore W2588961334C530470458 @default.
- W2588961334 hasConceptScore W2588961334C55493867 @default.
- W2588961334 hasConceptScore W2588961334C71924100 @default.
- W2588961334 hasConceptScore W2588961334C86803240 @default.
- W2588961334 hasConceptScore W2588961334C89423630 @default.
- W2588961334 hasIssue "27_suppl" @default.
- W2588961334 hasLocation W25889613341 @default.
- W2588961334 hasOpenAccess W2588961334 @default.
- W2588961334 hasPrimaryLocation W25889613341 @default.
- W2588961334 hasRelatedWork W1999292713 @default.
- W2588961334 hasRelatedWork W2053778437 @default.
- W2588961334 hasRelatedWork W2357773775 @default.
- W2588961334 hasRelatedWork W2367923615 @default.
- W2588961334 hasRelatedWork W2388892295 @default.
- W2588961334 hasRelatedWork W2498903697 @default.
- W2588961334 hasRelatedWork W2534174115 @default.
- W2588961334 hasRelatedWork W2554176272 @default.
- W2588961334 hasRelatedWork W2884115234 @default.
- W2588961334 hasRelatedWork W2892037304 @default.
- W2588961334 hasVolume "30" @default.
- W2588961334 isParatext "false" @default.
- W2588961334 isRetracted "false" @default.
- W2588961334 magId "2588961334" @default.
- W2588961334 workType "article" @default.